𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2

✍ Scribed by Marie-Bénédicte Leger-Ravet; Claire Mathiot; Alain Portier; Maud Brandely; Pierre Galanaud; Wolf-Herman Fridman; Dominique Emilie

Publisher
Springer-Verlag
Year
1994
Tongue
English
Weight
792 KB
Volume
39
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of subcutaneous recombinan
Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma
✍ Omar Eton; Michael G. Rosenblum; Sewa S. Legha; Wehei Zhang; Mary Jo East; Agop 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 3 views

## Abstract ## BACKGROUND Interleukin‐2 (IL‐2) has activity in metastatic melanoma when given in high doses by the intravenous (IV) route, but its side effects and effectiveness when given in intermediate to high doses by the subcutaneous (SC) route have not been studied adequately. This study sou

Evaluation of interleukin-2 administered
Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
✍ Sewa S. Legha; Mary Ann Gianan; Carl Plager; Omar E. Eton; Nicholas E. J. Papado 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 726 KB

## BACKGROUND. Interleukin-2 (IL-2) has been used widely in the treatment of advanced melanoma, most often using a high dose bolus schedule of administration. We have evaluated the antitumor activity and toxicity of IL-2 when administered by a continuous infusion schedule in patients with metastat